Delivering specific therapeutic plasmids to tumor cells to collaboratively enhance antitumor immunity, facilitating complex combination strategies previously impossible with traditional OVs.
Oncolytic Virus based Nanoparticle for Targeted Drug Delivery
Are you currently facing safety concerns, rapid host immune reaction, or limited target specificity in your cancer therapy pipeline? Our Oncolytic Viruses-Based Nanoparticles (OV-NPs) service helps you overcome these barriers and achieve targeted, multi-functional immune activation through rationally designed synthetic nanoparticles and advanced chemical modification. We transform the challenge of viral delivery into a highly controlled, safe, and effective therapeutic solution.
Click Here to View more about our Service
Introduction of Oncolytic Viruses-Based Nanoparticles
The therapeutic promise of traditional oncolytic viruses (OVs) lies in their innate ability to selectively lyse cancer cells while activating robust innate immune responses. However, their clinical application is severely limited by rapid clearance, neutralization by the host immune system, and challenges in systemic stability. Creative Biolabs provides VLP development services, including OV-NPs development. These platforms retain the core genetic and immunological advantages of OVs—such as tumor-specific payload delivery and immune stimulation—but replace the viral structure with a safer, more controllable synthetic carrier.
What are VLP-based NPs?
Creative Biolabs' VLP Development service focuses on the design, engineering, and scalable production of customized VLP nanoscaffolds. This service provides researchers and biotech companies with ready-to-use, high-purity, functionalized nanoparticles for complex biological applications.
Application Scenarios
Targeted Gene Combination Therapy
Active Immune Modulation
Designing the nanoparticle core or surface to activate specific intracellular pathways, driving a potent localized innate immune response.
Enhanced Systemic Stability
Providing chemical and physical protection to sensitive nucleic acid or protein payloads against degradation during systemic circulation.
Fig.1 Illustrative diagram of nanomaterials and nanotechnologies for OVs.1
Why Choose Us?
Zero Toxicity Profile
By eliminating the viral core, our synthetic OV-NPs are engineered to demonstrate a superior safety profile, minimizing the risk of adverse host immune reactions often seen with live viral vectors.
Programmable Immune Activation
We can precisely control the level and type of immune response by integrating specific adjuvants directly into the particle composition.
Superior Systemic Stability and Circulation
The modification of the NP shell significantly prolongs circulation time and ensures robust protection of the therapeutic payload.
High Payload Versatility
OV-NPs can efficiently encapsulate various payloads, from viral genomes and plasmids to small molecules, enabling rapid prototyping for diverse therapeutic targets.
Key Technologies
Engineering Key Points
Our engineering workflow focuses on three critical elements to maximize therapeutic index, moving beyond simple encapsulation to achieve sophisticated, programmable delivery:
We employ advanced chemical conjugation techniques, to shield the NP surface from opsonization and phagocytosis, maximizing systemic residence time.
The core is constructed using materials that not only protect the genetic payload but also serve as an active adjuvant to activate innate immunity upon cellular uptake.
We chemically modify the NP surface to present targeting ligands, ensuring superior tumor cell tropism and reducing off-target effects.
Find Out How We Can Help - Schedule a Consultation!
Cutting-Edge Technology
Biomimetic strategies, coating synthetic NP cores with natural cell membranes. This harnesses the inherent biological functions of the source cells, turning the NP into a stealth or actively homing vector.
| Membrane Source | Key Surface Features | Targeting Advantages | Application Examples |
|---|---|---|---|
| Macrophage | CD47 ("Don't Eat Me" signal), various receptors | Immune Evasion, Prolonged Circulation, Homing to inflammatory/tumor sites. | Delivery across the blood-brain barrier (BBB), chronic inflammation targeting. |
| Platelet | P-selectin, various adhesion molecules | Selective Adherence to Damaged Vasculature and Metastatic Tumor Cells. | Targeting inflamed endothelium, preventing tumor metastasis. |
| Cancer Cell | Tumor-Associated Antigens (TAAs), Homotypic binding markers | Homotypic Targeting (Cancer cell to Cancer cell), Enhanced Immunogenicity. | Personalized Cancer Vaccines, highly specific primary tumor targeting. |
QC Method: Building Trust and Reliability
Building trust and ensuring reliability are paramount. Rigorous Quality Control (QC) standards for every batch of custom OV-NPs to validate both physical integrity and functional performance.
Physicochemical Characterization
Use Dynamic Light Scattering (DLS) and Cryo-Electron Microscopy (Cryo-EM) to verify particle size, zeta potential, and morphology, ensuring consistent viral-like dimensions.
Payload Encapsulation Efficiency
Quantification of the encapsulated therapeutic payload (plasmid DNA, RNA, small molecule) using methods like spectrophotometry or HPLC to confirm loading capacity and structural stability.
In Vitro Functional Assays
Validation of the NP's functional mechanism, including measuring transfection efficiency and STING pathway activation assays.
In Vivo Safety and Efficacy Modeling
Pre-clinical testing to confirm zero toxicity and measure tumor suppression rates, providing robust functional data prior to large-scale production.
Key Benefits
Creative Biolabs' OV-NPs represent a quantum leap in therapeutic delivery, offering superior efficacy and safety driven by sophisticated bioengineering.
Truly Non-Toxic Design
By utilizing synthetic polymers, the platform avoids the inherent pathogenicity of viruses, ensuring treatments are effective without compromising patient safety.
Enhanced Immune-Checkpoint Agonism
Direct delivery of immune-modulating genes enables the reprogramming of the tumor microenvironment for superior T-cell engagement and sustained antitumor immunity.
Scalability and Reproducibility
Unlike cell-culture-dependent viral production, our synthetic OV-NPs offer robust, reproducible, and scalable manufacturing, significantly shortening development timelines and lowering production costs.
Amplify Your Edge with Creative Biolabs - Request a Quote Today!
Products
| Products | Description | Inquiry |
|---|---|---|
| Lipid Nanoparticle Products | LNPs, as a leading non-viral vector platform for nucleic acid delivery, are precisely engineered self-assembling systems designed to protect and deliver therapeutic payloads. |
Frequently Asked Questions
How can I be sure that the synthetic OV-NP will be as potent as a live virus?
Our OV-NPs are designed to be more potent by focusing power on specific mechanisms. We replace the uncontrolled immune response of a virus with a targeted, multi-functional system that delivers a therapeutic payload and activates innate immunity simultaneously.
What kind of payload can Creative Biolabs' OV-NPs encapsulate?
Our platform is highly versatile. We routinely encapsulate large genetic payloads (plasmid DNA, mRNA), smaller nucleic acids (siRNA), and various chemotherapeutic drugs. The core technology is adaptable, allowing us to customize the carrier to perfectly fit your specific therapeutic molecule. Let's discuss your unique payload requirements.
What precautions should be taken regarding off-target delivery?
Some rational design process prioritizes high specificity. Advanced surface engineering, including both chemical ligands and biomimetic cell membrane cloaking, can be used to achieve superior tumor-specific targeting, dramatically reducing the concentration of the therapeutic agent in healthy tissues.
Creative Biolabs is leading the shift in cancer immunotherapy from traditional viral vectors to advanced, safe, and programmable synthetic nanomedicine. Our Oncolytic Viruses-Based Nanoparticles (OV-NPs) development service delivers the next generation of targeted therapy, combining genetic reprogramming with active immune pathway activation to achieve unmatched clinical results. Partner with us to overcome the systemic stability and safety challenges of conventional OVT and realize the full potential of gene combination therapy.
Reference
- Zhang, Yan, et al. "Nanoengineering‐armed oncolytic viruses drive antitumor response: progress and challenges." MedComm 5.10 (2024): e755. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1002/mco2.755.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
